[
  {
    "ts": null,
    "headline": "Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds",
    "summary": "FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an overvaluation of 29.68%. See more.",
    "url": "https://finnhub.io/api/news?id=b3f0a1d6846b875ac53f5b93a59ac3e7c6b3608ddbfd9acc8ec241a8c1272fa1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751434838,
      "headline": "Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds",
      "id": 135709346,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182156897/image_2182156897.jpg?io=getty-c-w1536",
      "related": "CRL",
      "source": "SeekingAlpha",
      "summary": "FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an overvaluation of 29.68%. See more.",
      "url": "https://finnhub.io/api/news?id=b3f0a1d6846b875ac53f5b93a59ac3e7c6b3608ddbfd9acc8ec241a8c1272fa1"
    }
  }
]